Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo
Year: 2022
Type: article
Study design: Study Protocol
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.062382
Institutions: University of Nevada, Las Vegas, Sahlgrenska University Hospital, UK Dementia Research Institute, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London, University of Gothenburg, Brigham and Women's Hospital, Harvard University, Banner Health, Banner Sun Health Research Institute, Novo Nordisk (Denmark), University of Copenhagen, Gentofte Hospital, Novo Nordisk Foundation Center for Basic Metabolic Research, Steno Diabetes Center Copenhagen, Icahn School of Medicine at Mount Sinai, University of Eastern Finland, University of California San Diego
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4312088304